FARMACOSMO risk profile
58 Elevated one input has moved against it
Measured 1 September 2026 from COSMO.MI's filed statements. Recomputed nightly.
58 (Elevated), driven by Leverage and coverage at 96, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 73 | Stretched | Volatile | One-year price volatility — 63.6% |
| Operating pressure | 59 | Elevated | Worsening | Costs outgrowing revenue — +5.6 percentage points |
| Cash conversion | 89 | Acute | Stable | Capital spending against operating cash — 4.91x |
| Leverage and coverage | 96 | Acute | Worsening | Net debt to EBITDA — 18.74x |
| Competitive position | 33 | Normal | Stable | Revenue-growth gap against peers — -26.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.